SBWire

Global Markets Direct's, 'Promius Pharma, LLC - Product Pipeline Review - 2014', provides an overview of the Promius Pharma, LLC's pharmaceutical research and development focus.

Global Markets Direct's, 'Lipotek Pty Ltd. - Product Pipeline Review - 2014', provides an overview of the Lipotek Pty Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Nonmelanomatous Skin Cancer - Pipeline Review, H2 2014', provides an overview of the Nonmelanomatous Skin Cancer's therapeutic pipeline.

Global Markets Direct's, 'Toyama Chemical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Toyama Chemical Co., Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'NKT Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the NKT Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2014', provides an overview of the Pancreatic Ductal Adenocarcinoma's therapeutic pipeline.

Global Markets Direct's, 'SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014', provides an overview of the SymBio Pharmaceuticals Limited's pharmaceutical research and development focus.

Global Markets Direct's, 'Heron Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Heron Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'GliaCure Inc. - Product Pipeline Review - 2014', provides an overview of the GliaCure Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'ImmuRx, Inc. - Product Pipeline Review - 2014', provides an overview of the ImmuRx, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Neurotez, Inc. - Product Pipeline Review - 2014', provides an overview of the Neurotez, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Alitair Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Alitair Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Kite Pharma, Inc. - Product Pipeline Review - 2014', provides an overview of the Kite Pharma, Inc.'s pharmaceutical research and development focus.

Sickle-cell anemia is a disease characterized by the presence of sickle-shaped erythrocytes. While normal erythrocytes have a life span of 120 days, sickle-shaped erythrocytes die within 10 to 20 days. The bone marrow is unable to compensate for the excessive loss of erythrocytes, thereby leading to anemia. It is an inheritable disorder passed on across generations. The prevalence of the sickle-cell gene varies between different ethnic groups and geographical locations.

Global Markets Direct's, 'NovaRx Corporation - Product Pipeline Review - 2014', provides an overview of the NovaRx Corporation's pharmaceutical research and development focus.

Global Markets Direct's, 'ImmuVen, Inc. - Product Pipeline Review - 2014', provides an overview of the ImmuVen, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Kolltan Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Catalyst Biosciences, Inc. - Product Pipeline Review - 2014', provides an overview of the Catalyst Biosciences, Inc.'s pharmaceutical research and development focus.

GlobalData has released its new PharmaPoint Drug Evaluation report, "MGN1703 (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Actinium Pharmaceuticals, Inc, a New York City-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a request for a CMC (Chemistry, Manufacturing and Control) meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug candidate currently undergoing preparations for starting the pivotal Phase 3 trial by the middle of 2015. The Company expects to obtain further guidance from the FDA that will allow completion of the processes and methods for large scale manufacturing and testing of clinical and commercial grade drug product.

Advanced Accelerator Applications S.A. ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), announced that it has acquired the remaining 49.9% of Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company headquartered in Ottawa, Canada and focused on the development of proprietary molecular imaging products aimed at imaging apoptosis and necrosis based on Annexin V. Atreus Pharmaceuticals Corporation is now a fully owned AAA subsidiary and has been renamed AAA Canada.

Global Markets Direct's, 'Ambryx Biotechnology, Inc. - Product Pipeline Review - 2014', provides an overview of the Ambryx Biotechnology, Inc.'s pharmaceutical research and development focus.

St. Louis Pharmacy technician schools are offering certified degrees through Midwest Institute with an aim to help those who want to take up the career of a pharmacy technician. The career of a pharmacy technician has been witnessing an upward trend and there is a very good demand for this career.

GlobalData has released its new PharmaPoint Drug Evaluation report, "Stivarga (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Global Markets Direct's, 'Tesaro, Inc. - Product Pipeline Review - 2014', provides an overview of the Tesaro, Inc.'s pharmaceutical research and development focus.